Corbus Pharmaceuticals I... (CRBP)
Corbus Pharmaceuticals Statistics
Share Statistics
Corbus Pharmaceuticals has 12.23M shares outstanding. The number of shares has increased by 14.46% in one year.
| Shares Outstanding | 12.23M |
| Shares Change (YoY) | 14.46% |
| Shares Change (QoQ) | 0.43% |
| Owned by Institutions (%) | 0% |
| Shares Floating | 10.55M |
| Failed to Deliver (FTD) Shares | 14.88K |
| FTD / Avg. Volume | 6.3% |
Short Selling Information
The latest short interest is 2.47M, so 20.21% of the outstanding shares have been sold short.
| Short Interest | 2.47M |
| Short % of Shares Out | 20.21% |
| Short % of Float | 25.18% |
| Short Ratio (days to cover) | 10.36 |
Valuation Ratios
The PE ratio is -3.2 and the forward PE ratio is -1.73. Corbus Pharmaceuticals's PEG ratio is 0.05.
| PE Ratio | -3.2 |
| Forward PE | -1.73 |
| PS Ratio | 0 |
| Forward PS | 0.7 |
| PB Ratio | 0.9 |
| P/FCF Ratio | -3.08 |
| PEG Ratio | 0.05 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Corbus Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.94, with a Debt / Equity ratio of 0.02.
| Current Ratio | 12.94 |
| Quick Ratio | 12.94 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | - |
| Debt / FCF | -0.08 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.44M |
| Employee Count | 28 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -76.38% in the last 52 weeks. The beta is 3.13, so Corbus Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 3.13 |
| 52-Week Price Change | -76.38% |
| 50-Day Moving Average | 6.61 |
| 200-Day Moving Average | 23.44 |
| Relative Strength Index (RSI) | 69.74 |
| Average Volume (20 Days) | 236.4K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | 0 |
| Net Income | -40.21M |
| EBITDA | 0 |
| EBIT | n/a |
| Earnings Per Share (EPS) | -3.68 |
Balance Sheet
The company has 17.2M in cash and 3.24M in debt, giving a net cash position of 13.96M.
| Cash & Cash Equivalents | 17.2M |
| Total Debt | 3.24M |
| Net Cash | 13.96M |
| Retained Earnings | -476.89M |
| Total Assets | 155.88M |
| Working Capital | 141.16M |
Cash Flow
In the last 12 months, operating cash flow was -41.79M and capital expenditures 0, giving a free cash flow of -41.79M.
| Operating Cash Flow | -41.79M |
| Capital Expenditures | 0 |
| Free Cash Flow | -41.79M |
| FCF Per Share | -3.83 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CRBP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CRBP is $52, which is 542.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $52 |
| Price Target Difference | 542.8% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Stock Splits
The last stock split was on Feb 14, 2023. It was a backward split with a ratio of 1:30.
| Last Split Date | Feb 14, 2023 |
| Split Type | backward |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | 0.52 |
| Piotroski F-Score | 1 |